Clinical Trial

A Study to Assess How the Body Absorbs ABBV-8736 Subcutaneous Injections Relative to Intravenous Injections in Adult Healthy Volunteers

Completed Phase 1
View on ClinicalTrials.gov →
Summary
The purpose of this study is to assess the pharmacokinetics (PK), bioavailability, immunogenicity, safety, and tolerability of ABBV-8736 following subcutaneous (SC) administration relative to intravenous (IV) administration.
Protocol Amendment History 2 changes
critical Trial completed 2026-07-21
critical Trial status changed: RECRUITING → ACTIVE_NOT_RECRUITING 2026-04-29
Trial Details
NCT Number NCT07413133
Lead Sponsor AbbVie
Conditions Healthy Volunteer
Enrollment 40 participants
Start Date 2026-02-11
Primary Completion 2026-06-19 (estimated)
Study Completion 2026-06-19 (estimated)
Updated on ClinicalTrials.gov 2026-07-20